文献速递角膜与眼表疾病

重组人神经生长因子治疗神经营养性角膜炎的II期随机对照试验

Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
PubMed 文献 · Ophthalmology · 2018-04-10

REPARO II期多中心随机双盲赋形剂对照试验纳入156例2期或3期神经营养性角膜炎患者,按1:1:1随机接受rhNGF 10 μg/ml、20 μg/ml或赋形剂点眼,每日6滴、共8周。第4周角膜愈合率赋形剂组19.6%,rhNGF 10 μg/ml组54.9%、20 μg/ml组58.0%,差异均具统计学意义。作者结论为局部rhNGF安全且较赋形剂更有效促进中重度神经营养性角膜炎愈合。

要点

  • 第4周角膜愈合率:赋形剂组19.6% vs rhNGF 10 μg/ml组54.9% vs 20 μg/ml组58.0%
  • 第8周角膜愈合率:赋形剂组43.1% vs rhNGF 10 μg/ml组74.5% vs 20 μg/ml组74.0%
  • 接受rhNGF治疗愈合者中逾96%在随访期无复发,不良反应多为局部、轻度和一过性

核心结论

  • 局部rhNGF安全,且较赋形剂更有效促进中重度神经营养性角膜炎的角膜愈合。

研究设计与样本

  • II期多中心、随机、双盲、赋形剂对照试验;156例单眼2期(中度)或3期(重度)神经营养性角膜炎患者按1:1:1随机分为rhNGF 10 μg/ml组、20 μg/ml组和赋形剂组。
  • 治疗为每日6滴、持续8周,随后进入48周或56周随访期;安全性分析纳入所有接受研究治疗的患者,疗效分析采用意向性治疗。
  • 角膜愈合由设盲的中心阅片者于对照治疗第4周(主要疗效终点)和第8周(关键次要终点)评估。

主要发现

  • 第4周(主要终点)达到角膜愈合(病灶荧光素染色最大直径<0.5 mm)者:赋形剂组19.6%,rhNGF 10 μg/ml组54.9%(+35.3%;97.06%CI 15.88-54.71;P<0.001),rhNGF 20 μg/ml组58.0%(+38.4%;97.06%CI 18.96-57.83;P<0.001)。
  • 第8周(关键次要终点)病灶染色<0.5 mm者:赋形剂组43.1%,rhNGF 10 μg/ml组74.5%(+31.4%;97.06%CI 11.25-51.49;P=0.001),rhNGF 20 μg/ml组74.0%(+30.9%;97.06%CI 10.60-51.13;P=0.002)。
  • 事后分析采用更严格的愈合标准(病灶区0 mm染色且无其他持续染色),第4周和第8周rhNGF与赋形剂间差异仍具统计学意义。
  • 对照治疗期间经rhNGF治疗愈合的患者中,逾96%在随访期保持无复发。
  • rhNGF耐受性良好,不良反应多为局部、轻度和一过性。

关键数值与推荐

  • 角膜愈合定义:病灶区荧光素染色最大直径<0.5 mm,由设盲中心阅片者评估。
  • 更严格的事后愈合标准:病灶区0 mm染色且无其他持续染色。
  • 给药方案:rhNGF 10 μg/ml或20 μg/ml,每日6滴,持续8周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation. DESIGN: Phase II multicenter, randomized, double-masked, vehicle-controlled trial. PARTICIPANTS: Patients with stage 2 (moderate) or stage 3 (severe) NK in 1 eye. METHODS: The REPARO phase II study assessed safety and efficacy in 156 patients randomized 1:1:1 to rhNGF 10 μg/ml, 20 μg/ml, or vehicle. Treatment was administered 6 drops per day for 8 weeks. Patients then entered a 48- or 56-week follow-up period. Safety was assessed in all patients who received study treatment, whereas efficacy was by intention to treat. MAIN OUTCOME MEASURES: Corneal healing (defined as <0.5-mm maximum diameter of fluorescein staining in the lesion area) was assessed by masked central readers at week 4 (primary efficacy end point) and week 8 (key secondary end point) of controlled treatment. Corneal healing was reassessed post hoc by masked central readers using a more conservative measure (0-mm staining in the lesion area and no other persistent staining). RESULTS: At week 4 (primary end point), 19.6% of vehicle-treated patients achieved corneal healing (<0.5-mm lesion staining) versus 54.9% receiving rhNGF 10 μg/ml (+35.3%; 97.06% confidence interval [CI], 15.88-54.71; P < 0.001) and 58.0% receiving rhNGF 20 μg/ml (+38.4%; 97.06% CI, 18.96-57.83; P < 0.001). At week 8 (key secondary end point), 43.1% of vehicle-treated patients achieved less than 0.5-mm lesion staining versus 74.5% receiving rhNGF 10 μg/ml (+31.4%; 97.06% CI, 11.25-51.49; P = 0.001) and 74.0% receiving rhNGF 20 μg/ml (+30.9%; 97.06% CI, 10.60-51.13; P = 0.002). Post hoc analysis of corneal healing by the more conservative measure (0-mm lesion staining and no other persistent staining) maintained statistically significant differences between rhNGF and vehicle at weeks 4 and 8. More than 96% of patients who healed after controlled rhNGF treatment remained recurrence free during follow-up. Treatment with rhNGF was well tolerated; adverse effects were mostly local, mild, and transient. CONCLUSIONS: Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate-to-severe NK.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Bonini S, Lambiase A, Rama P, et al. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. Ophthalmology. 2018. PMID: 29653858. doi:10.1016/j.ophtha.2018.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。